You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: February 17, 2025

Drug Price Trends for SEVELAMER HCL


✉ Email this page to a colleague

« Back to Dashboard


Drug Price Trends for SEVELAMER HCL

Average Pharmacy Cost for SEVELAMER HCL

These are average pharmacy acquisition costs (net of discounts) from a US national survey
Drug Name NDC Price/Unit ($) Unit Date
SEVELAMER HCL 800 MG TABLET 60687-0449-01 1.34994 EACH 2025-01-22
SEVELAMER HCL 800 MG TABLET 33342-0242-57 1.34994 EACH 2025-01-22
SEVELAMER HCL 800 MG TABLET 59651-0088-18 1.34994 EACH 2025-01-22
SEVELAMER HCL 800 MG TABLET 60687-0449-11 1.34994 EACH 2025-01-22
SEVELAMER HCL 800 MG TABLET 00955-1048-18 1.34994 EACH 2025-01-22
>Drug Name >NDC >Price/Unit ($) >Unit >Date

Best Wholesale Price for SEVELAMER HCL

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available to any customer under comparable terms and conditions
Drug Name Vendor NDC Count Price ($) Price/Unit ($) Unit Dates Price Type
SEVELAMER HCL 800MG TAB AvKare, LLC 68462-0447-18 180 307.27 1.70706 EACH 2023-06-15 - 2028-06-14 FSS
SEVELAMER HCL 800MG TAB Sanofi Aventis U.S. LLC 00955-1048-18 180 91.66 0.50922 EACH 2024-01-01 - 2028-05-31 Big4
SEVELAMER HCL 800MG TAB Sanofi Aventis U.S. LLC 00955-1048-18 180 128.04 0.71133 EACH 2024-01-01 - 2028-05-31 FSS
SEVELAMER HCL 800MG TAB Sanofi Aventis U.S. LLC 00955-1048-18 180 158.95 0.88306 EACH 2023-06-01 - 2028-05-31 Big4
SEVELAMER HCL 800MG TAB Sanofi Aventis U.S. LLC 00955-1048-18 180 158.95 0.88306 EACH 2023-06-01 - 2028-05-31 FSS
>Drug Name >Vendor >NDC >Count >Price ($) >Price/Unit ($) >Unit >Dates >Price Type
Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Market Analysis and Price Projections for Sevelamer HCL

Introduction to Sevelamer HCL

Sevelamer, often referred to in its hydrochloride or carbonate forms, is a crucial medication in the management of hyperphosphatemia, particularly in patients with chronic kidney disease (CKD) and those undergoing dialysis. It belongs to the class of phosphate binders, which work by binding to phosphates in the intestine and preventing their absorption into the bloodstream.

Market Size and Growth Projections

The global market for Sevelamer is anticipated to experience significant growth over the coming years. As of 2023, the market was estimated to be worth approximately $220 million. However, it is forecasted to expand to a readjusted size of $337.1 million by 2030, with a Compound Annual Growth Rate (CAGR) of 6.2% during the forecast period of 2024-2030[1].

Key Market Drivers

Several factors are driving the growth of the Sevelamer market:

Increasing Prevalence of Chronic Kidney Disease

The rising incidence of CKD and the subsequent need for effective phosphate control are major drivers. Sevelamer's efficacy in managing hyperphosphatemia in these patients makes it a preferred treatment option[4].

Regulatory Approvals

The US Food and Drug Administration (FDA) has authorized Sevelamer for the treatment of hyperphosphatemia in individuals on hemodialysis with chronic renal impairment, further boosting its demand[4].

Convenience and Efficacy

Sevelamer's formulations, including tablets and oral powders, offer convenience and comparable effectiveness regardless of the number of dosages, making it a preferred choice among healthcare providers[4].

Market Challenges

Despite the positive growth projections, there are several challenges that could impact the market:

Side Effects and Health Hazards

Sevelamer is associated with gastrointestinal side effects, pleiotropic effects such as increased serum lipid profiles, and risks of intestinal blockage and ileus/subileus. These health hazards can reduce patient preference and compliance[4].

Higher Acquisition Costs

The higher costs of Sevelamer formulations can restrain market revenue growth. Patients often face significant expenses, especially those without adequate insurance coverage[4].

Key Players in the Market

The Sevelamer market is dominated by several major pharmaceutical companies, including:

  • Sanofi
  • Impax Laboratories
  • InvaGen Pharmaceuticals
  • Dr. Reddy's Laboratories
  • Aurobindo Pharma
  • Amneal Pharmaceuticals[1].

These companies play a crucial role in manufacturing, marketing, and distributing Sevelamer products globally.

Pricing and Cost Analysis

The cost of Sevelamer can vary significantly based on the formulation and quantity:

Oral Tablets

  • A supply of 50 Sevelamer carbonate 800 mg oral tablets can cost around $57, depending on the pharmacy and any available discounts or coupons[2].

Oral Powder for Reconstitution

  • The cost for 90 powder for reconstitution can range from $682.57 for the 2.4 g formulation to $763.97 for the 0.8 g formulation[2].

Regional Market Analysis

The demand for Sevelamer is not uniform across all regions. The market is influenced by factors such as the prevalence of CKD, healthcare infrastructure, and regulatory environments.

North America and Europe

These regions are expected to contribute significantly to the market growth due to advanced healthcare systems and higher awareness of CKD management.

Asia-Pacific

This region is also anticipated to show rapid growth due to an increasing patient population and improving healthcare facilities[1].

Competitive Landscape

The competitive landscape of the Sevelamer market is characterized by intense competition among the key players. Companies are focusing on improving formulations, enhancing patient compliance, and expanding their market reach through strategic partnerships and marketing efforts.

Future Outlook

The future outlook for the Sevelamer market is promising, driven by the increasing need for effective phosphate control in CKD patients. However, addressing the challenges related to side effects and high acquisition costs will be crucial for sustained growth.

Key Takeaways

  • Market Growth: The global Sevelamer market is expected to grow from $220 million in 2023 to $337.1 million by 2030, with a CAGR of 6.2%.
  • Key Drivers: Increasing prevalence of CKD, regulatory approvals, and the convenience and efficacy of Sevelamer formulations.
  • Challenges: Side effects, health hazards, and higher acquisition costs.
  • Key Players: Sanofi, Impax Laboratories, InvaGen Pharmaceuticals, Dr. Reddy's Laboratories, Aurobindo Pharma, and Amneal Pharmaceuticals.
  • Pricing: Varies by formulation and quantity, with significant costs for oral tablets and powders.

FAQs

Q1: What is Sevelamer used for? Sevelamer is used to control hyperphosphatemia in adult patients receiving hemodialysis or peritoneal dialysis with chronic nephropathy[3].

Q2: What are the common side effects of Sevelamer? Common side effects include nausea, vomiting, diarrhea, and gastrointestinal issues. It can also lead to intestinal blockage and ileus/subileus[4][5].

Q3: Which companies are the main players in the Sevelamer market? The main players include Sanofi, Impax Laboratories, InvaGen Pharmaceuticals, Dr. Reddy's Laboratories, Aurobindo Pharma, and Amneal Pharmaceuticals[1].

Q4: How much does Sevelamer cost? The cost varies by formulation and quantity. For example, 50 Sevelamer carbonate 800 mg oral tablets can cost around $57, and 90 powder for reconstitution can range from $682.57 to $763.97[2].

Q5: What is the forecasted market size of Sevelamer by 2030? The global Sevelamer market is forecasted to reach $337.1 million by 2030, with a CAGR of 6.2% during the forecast period of 2024-2030[1].

Sources

  1. Valuates Reports: Sevelamer - Market, Report Size, Worth, Revenue, Growth, Industry ...
  2. Drugs.com: Sevelamer Prices, Coupons, Copay Cards & Patient Assistance
  3. GlobalData: Net Present Value Model: Sevelamer Carbonate
  4. Reports and Data: Sevelamer Carbonate Market
  5. Pharmeasy: Sevelamer 400 MG Tablet (10): Uses, Side Effects, Price & Dosage

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.